STUDY ON PREVALENCE OF ADVERSE DRUG REACTIONS IN PATIENTS SUFFERING FROM TUBERCULOSIS IN A TERTIARY CARE HOSPITAL
Keywords:
Prevalence, Tuberculosis, Adverse Drug ReactionAbstract
Objective: To study the prevalence of ADRs associated with the use of anti-tubercular drugs in patients with tuberculosis in a tertiary care hospital.
Methods: A prospective observational and active surveillance study was conducted in the department of pulmonology and DOTS Centre in Owaisi Hospital and Research Centre over a period of 6 mo after the study was approved by IRB. The patients who gave informed consent were included in the study and their information was analysed after being recorded in a data collection form.
Results: Descriptive statistical analysis was carried out to generate results, the continuous measurement being presented as mean standard deviation (min-max) and categorical measurement presented in number (%). The results showed the prevalence of ADRs to be 69%. The prevalence of ADRs was more in females (55%) than in males (45%) and 75.9% of them reporting more than 1 ADR. ADR's affecting the skin and appendages were high (23.56%) while ADR's affecting gastrointestinal system (19.28%), the hepatic system (4.28%), the musculoskeletal system (15.7%), Central and peripheral nervous system (7.85%), Vision (0.7%) were comparatively less.
Conclusion: The study highlighted the importance of developing strategies to ameliorate ADRs both to improve the quality of patient care and to control TB safely.Â
Downloads
References
Haslett C, Chilvers ER, Corris PA. Tuberculosis. In: Haslett C, Chilvers ER, Boon NA, Colledge NR. Davidson’s principles and practice of medicine. 19th ed. London: Churchill Livingstone; 2002. p. 532-40.
Tuberculosis. In: Beers MH, Fletcher AJ, Porter R, Berkwits M. The Merck manual of medical information. 2nd ed. White house station: Merck Research Laboratories; 2003. p. 1125-30.
Chhetri AK, Saha A, Verma SC, Palani S, Mishra P, Shankar PR. A study of adverse drug reactions caused by first line antitubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara. J Pak Med Assoc 2008;58:531-6.
Tak DK, Acharya LD, Gowrinath K, Padma GMR, Subish P. Safety evaluation of anti-tubercular therapy under revised national Tuberculosis control program in India. J Clin Diagn Res 2009;3:1395-401.
Koju D, Rao BS, Shrestha B, Shakya R, Makaju R. Occurrence of side effects of anti-Tuberculosis drugs in urban Nepalese population under DOTS treatment. Kathmandu University J Sci Eng Technol 2005;1;1-8.
Ghosh S, Malik SKr, Gupta A, Chaudhary R. A prospective, observational cohort study to elicit adverse effects of antituberculosis drugs among patients treated for active tuberculosis. Pharm Res 2010;3:10-6.